• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Chiesi to distribute Kamada’s inhaled AAT

Israeli biopharmaceutical company Kamada will receive milestone payments of $60 million as part of a 12-year distribution agreement with Chiesi Farmaceutici for Kamada’s inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH). Chiesi will distribute the inhalation solution in Europe, Turkey and former CIS countries. Kamada expects clinical studies to be completed in 2013 and expects to launch the product in 2015.

Kamada CEO David Tsur commented, “I’m proud and pleased with this strategic distribution agreement for the inhaled AAT product. . . . Chiesi is an ideal partner for Kamada for its specialty, large experience and impressive reputation in the respiratory market. This allows us to best prepare for market penetration immediately after the successful completion of the pivotal clinical trial and receipt of all necessary approvals. I’m confident that Kamada’s advanced technology alongside Chiesi’s sales and marketing abilities will ensure the success of this partnership.”

“We are glad to add Inhaled AAT to our already strong late stage pipeline as it represents a perfect fit with Chiesi strategy, being a special care product with Orphan Drug status targeting a respiratory disease, consolidating our leadership position in some key countries,” said Chiesi CEO Ugo Di Francesco.

Kamada is also developing inhaled AAT for the treatment of cystic fibrosis and bronchiectasis.

Read the Kamada and Chiesi press release.

Share

published on August 6, 2012

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews